VTVT - vTv Therapeutics: A Promising Small Molecule Drug Discovery Pick For 2020
Today, we will see why vTv Therapeutics (VTVT) is a promising pick for 2020.
Company overview
Founded in 2015, vTv Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapies for the treatment of Alzheimer’s disease, diabetes, and inflammatory disorders. The company aims to provide protection solutions for the brain, pancreas, and liver from long-term complications associated with various metabolic diseases.
vTv Therapeutics is currently evaluating oral small molecule RAGE (receptor for advanced glycation endproducts) antagonist therapy, Azeliragon, for treatment of dementia in diabetes patients. The company is